Consensus Third Harmonic Bio, Inc.

Equities

THRD

US88427A1079

Real-time Estimate Cboe BZX Other stock markets 10:37:14 2024-05-20 am EDT			5-day change	1st Jan Change
14.3 ^USD	+3.10%		+17.99%	+29.72%

May. 15	Third Harmonic Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 15	Third Harmonic Bio, Inc. Announces the Appointment and Promotion of Key Executive Leaders to the Organization	CI

Evolution of the average Target Price on Third Harmonic Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a750298e3aad1cb2b66737.lXRLNTRxoCFpREkl-dHOaRZnk54ybm29YTcLClk2cgg.wEcKckQ_11AxFz5EiamNL3BRo9gFKg_VG2NsRDFvGUP6ES19eEPFbQccAA~d7ae7482bbb32e12db46890aec366a99

Analyst Recommendations on Third Harmonic Bio, Inc.

Morgan Stanley Adjusts Price Target on Third Harmonic Bio to $7 From $5, Maintains Equalweight Rating	23-08-11	MT
LifeSci Capital Downgrades Third Harmonic Bio to Market Perform From Outperform	22-12-16	MT
Morgan Stanley Downgrades Third Harmonic Bio to Equalweight From Overweight, Slashes Price Target to $5 From $34	22-12-16	MT
Jefferies Downgrades Third Harmonic Bio to Hold From Buy, Slashes Price Target to $3.60 From $30	22-12-16	MT
Jefferies & Co Initiates Coverage on Third Harmonic Bio With Buy Rating, $30 Price Target	22-10-10	MT
Morgan Stanley Starts Third Harmonic Bio at Overweight With $34 Price Target	22-10-10	MT
Cowen Starts Third Harmonic Bio at Outperform	22-10-10	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.86 USD

Average target price

13.5 USD

Spread / Average Target

-2.63%

High Price Target

15 USD

Spread / Highest target

+8.19%

Low Price Target

12 USD

Spread / Lowest Target

-13.45%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Third Harmonic Bio, Inc.

Morgan Stanley
Jefferies & Co.
LifeSci Capital
Cowen

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar